Key facts
- This page summarizes David Charles Link's Form 4 filing for SAB Biotherapeutics, Inc. (SABS).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Jul 2024, 16:30.
David Charles Link - 15 Jul 2024 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)
- Reporting relationship
- Director
- Issuer ticker
- SABS
- Reported as of
- 15 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jul 2024, 16:30:07 UTC
- Prior SEC filing
- 09 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Charles Link
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Charles Link filed Form 4 for SAB Biotherapeutics, Inc. (SABS) on 17 Jul 2024.
Change
- Previous filing in this sequence was filed on 09 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SABS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 15 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $2.90
- Footnotes
- F1, F3
SABS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +9,305
- Change %
- Price
- $0.000000
- Shares after
- 9,305
- Date
- 15 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,305
- Exercise price
- $2.90
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.
Footnote F2
Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027.
Footnote F3
This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.